The Global HIV Vaccine Enterprise was established in 2003 as a collaborative global effort to promote the development of a safe and effective HIV vaccine. The Bill & Melinda Gates Foundation set out to advance this mission by contributing more than $287 million in support of HIV vaccine development and discovery. The Foundation awarded funds to eleven consortia that will focus on novel methods in HIV vaccine design and five central laboratories and data analysis facilities that will provide state-of-the-art technologies to evaluate HIV vaccine candidates.
Mother to Infant HIV Vaccine Research and Development
Mission: To develop and perform preclinical testing of maternal and infant HIV vaccine regimens that aim to prevent infant HIV-1 infection
The Duke Regional Biocontainment Laboratory (GHRB) supports a comprehensive sponsored research portfolio with a focus on Vaccine and Therapeutic Development.